Lab21 announces sale of South Carolina Operations

14-Jan-2013 - Lab21 Limited announced the sale of its laboratory operations based in South Carolina to Reedy Acquisitions Corp, an entity formed by the existing local management and South Carolina based investors. In addition to an immediate cash benefit for Lab21 Ltd, the sale will remove a loss-making ...

Lab21 Wins Biomedical Project of the Year Award

01-Dec-2011 - Lab21 Limited has won the BioNow Biomedical Project of the Year Award for its MycAssay product line. The BioNow Biomedical Project of the Year Award recognises individuals or organisations who have demonstrated an innovative solution to a specific industry problem. Lab21’s MycAssay Aspergillus ...

Lab21 Announces Positive Results for Aspergillus Detection in Critical Care and Haematology Patients

14-Nov-2011 - Lab21 Limited has announced the completion of an evaluation of a commercial PCR test, its MycAssayTM Aspergillus assay, to detect invasive Aspergillosis (IA) in a mixed population of 158 patients with underlying haematological or critical illness. The prospective evaluation was performed by ...

Lab21 Extends CPA Accreditation

02-Nov-2011 - Lab21 Limited has announced that its Clinical Laboratory Division has extended its Clinical Pathology Accreditation (CPA) scope to include Molecular Biology and Virology in addition to Biochemistry. The accreditation was awarded by Clinical Pathology Accreditation (UK), the quality assurance ...

Lab21 acquires molecular diagnostics company Myconostica Ltd

25-May-2011 - Lab21 Limited has announced that it has acquired Myconostica Ltd. The financial terms of the deal were not disclosed. The acquisition of Myconostica expands Lab21’s growing proprietary diagnostic portfolio and will provide the Company’s first set of nucleic acid-based assays. Furthermore it will ...

Lab21 expands its range of cardiovascular genetic tests with Clinical Data, Inc.

29-Sep-2008 - Lab21 announced the expansion of its portfolio of genetic tests for inherited cardiac syndromes. Through its existing UK licence with PGxHealth™, a division of Clinical Data, Inc., Lab21 offers exclusive U.K. and Ireland access to the Familion® portfolio of tests for Long QT and Brugada ...

Lab21 acquires NPTech Ltd and appoints corporate advisors for European M&A activity

27-Mar-2008 - Lab21 has acquired NPTech Ltd, an independent clinical laboratory company providing diagnostic testing services for the NHS and private healthcare providers in the UK and parts of Europe. The acquisition of NPTech, in an undisclosed financial transaction, significantly broadens Lab21's range of ...

Predictive genetic test for bowel cancer treatment is introduced in the UK

Amgen and Lab21 in Partnership Agreement for New Cancer Therapy Test

20-Mar-2008 - Amgen Limited UK and Lab21 have announced their partnership to introduce a new genetic therapy test for advanced bowel cancer treatment in the UK. Under the terms of the agreement, Lab21 will provide a screening test to indicate which patients are likely to benefit from Amgen's new drug for ...

Lab21 signs a license with Celera for one of the first diagnostic tests for cirrhosis risk in hepatitis C patients

25-Feb-2008 - Lab21 announced that it has obtained a licence from Celera, an Applera Corporation business, to provide access to its test for cirrhosis risk in patients with chronic hepatitis C viral (HCV) infection in the UK and Ireland. The test, known as CRS7, is the first clinical test capable of ...

Lab21 launches cancer gene testing service

28-Jan-2008 - Lab21 announced the launch of a cancer gene testing service from its Cambridge laboratories. Lab21 is providing a test for analysis of the K-ras gene. K-ras plays an important role in cell growth regulation and the proliferation of cancer cells. In around 40% of cancer patients the K-ras gene is ...